Evaluating effects of switching anti–vascular endothelial growth factor drugs for age-related macular degeneration and diabetic macular edema
FL Ferris, MG Maguire, AR Glassman, G Ying… - JAMA …, 2017 - jamanetwork.com
Importance When a patient with neovascular age-related macular degeneration or diabetic
macular edema does not respond to an initial anti–vascular endothelial growth factor agent,
usually after several injections, ophthalmologists may switch to another anti–vascular
endothelial growth factor agent. Authors of case series have suggested beneficial effects
from switching. However, to our knowledge, there are no studies with an appropriate control
group to evaluate how such patients would do without switching agents. Objective To assess …
macular edema does not respond to an initial anti–vascular endothelial growth factor agent,
usually after several injections, ophthalmologists may switch to another anti–vascular
endothelial growth factor agent. Authors of case series have suggested beneficial effects
from switching. However, to our knowledge, there are no studies with an appropriate control
group to evaluate how such patients would do without switching agents. Objective To assess …
